past
decad
half
character
numer
emerg
infecti
diseas
new
threat
call
rapid
vaccin
develop
pathogen
middl
east
respiratori
syndrom
coronaviru
merscov
zika
viru
repres
either
new
viral
entiti
virus
emerg
new
geograph
local
character
novel
complic
serv
paradigm
global
spread
accompani
new
pathogen
paper
review
epidemiolog
pathogenesi
merscov
zika
viru
respect
vaccin
develop
challeng
vaccin
develop
approach
clinic
trial
design
test
vaccin
candid
diseas
entiti
chang
epidemiolog
discuss
case
progress
pulmonari
infect
relat
individu
resid
travel
arabian
peninsula
determin
caus
novel
group
c
bcoronaviru
merscov
contrast
major
human
pathogen
coronavirus
caus
selflimit
upperrespiratori
ill
mortal
rate
earli
merscov
case
approxim
remain
greater
approxim
seen
west
african
ebola
viru
outbreak
contrast
mortal
rate
sever
acut
respiratori
syndrom
coronaviru
sarscov
epidem
follow
incub
period
week
merscov
caus
rapidli
progress
lower
respiratori
infect
prodrom
ill
character
fever
cough
mild
short
breath
clinic
deterior
typic
lead
need
intens
care
ventil
support
past
decad
half
punctuat
multipl
global
infecti
threat
tabl
epidem
new
influenza
variant
novel
coronavirus
enterovirus
new
strain
ebola
viru
emerg
zika
viru
chikungunya
region
world
previous
unaffect
creat
signific
concern
healthcar
minim
time
identif
diseas
control
global
tourism
busi
complic
diseas
epidemiolog
may
local
pose
greater
potenti
intern
spread
approach
emerg
infecti
diseas
eid
mitig
differ
base
respect
pathogen
exampl
recent
outbreak
associ
porcin
avian
exposur
risk
infect
addit
introduct
pathogen
new
region
may
alter
epidemiolog
diseas
although
ebola
viru
outbreak
occur
sporad
sinc
appear
major
popul
center
west
africa
result
signific
amplif
transmiss
seen
prior
geograph
limit
outbreak
middl
east
respiratori
syndrom
coronaviru
merscov
repres
new
viral
entiti
relat
minim
pathogen
coronavirus
caus
highli
lethal
syndrom
wherea
zika
viru
recogn
african
east
asia
almost
decad
emerg
western
hemispher
recognit
heretofor
unrecogn
complic
includ
congenit
microcephali
guillain
barr
syndrom
gb
vaccin
consid
critic
compon
diseas
prevent
eid
especi
sinc
case
treatment
option
limit
nonexist
rapid
clinic
deterior
may
limit
effect
therapeut
howev
eid
vaccin
develop
desir
rapid
deploy
vaccin
newli
emerg
diseas
temper
realiti
lifecycl
drug
develop
paper
review
epidemiolog
clinic
present
merscov
zika
viru
regard
vaccin
develop
particular
challeng
clinic
trial
design
efficaci
studi
consid
discuss
particular
diseas
may
limit
scope
andor
epidemiolog
chang
realtim
within
day
present
hospit
complic
merscov
includ
renal
failur
cardiac
arrhythmia
merscov
epidem
punctuat
larg
healthcar
associ
dialysi
unit
outbreak
persontoperson
spread
famili
member
document
repres
small
minor
transmiss
event
contact
camel
consid
signific
risk
infect
direct
evid
cameltohuman
transmiss
report
other
question
certainti
direct
transmiss
suggest
report
case
sourc
infect
unknown
human
serv
vector
global
spread
mer
case
across
europ
north
america
asia
eman
travel
saudi
arabia
qatar
oman
uae
kuwait
secondari
infect
infrequ
report
earli
travelassoci
case
howev
global
epidem
potenti
merscov
exemplifi
fact
businessman
return
middl
east
seoul
korea
serv
index
case
subsequ
case
merscov
mortal
rate
despit
earli
diagnosi
intens
support
care
latter
outbreak
larg
part
due
breakdown
basic
infect
control
spread
beyond
arabian
peninsula
appear
avoid
activ
screen
quarantin
return
travel
similar
sarscov
group
b
b
coronaviru
merscov
consid
bat
origin
phylogenet
analysi
merscov
map
strain
group
c
node
strain
includ
tyloncyteri
bat
coronaviru
pipistrellu
bat
coronaviru
analysi
sampl
taken
bat
proxim
merscov
case
saudi
arabia
detect
sequenc
nucleotid
ident
rnadepend
rna
polymeras
merscov
strain
fecal
materi
one
anim
merscov
util
dipeptidyl
dipeptidas
cell
surfac
receptor
howev
highli
homolog
merscov
util
cell
entri
moreov
prefer
bat
human
wherea
opposit
true
merscov
thu
wherea
sarscov
util
angiotensin
convert
enzym
receptor
conserv
across
mammalian
speci
merscov
bind
genet
variant
analog
express
human
nonhuman
primat
bat
camelid
emerg
merscov
novel
human
pathogen
remain
mysteri
first
genet
alter
allow
viru
caus
mild
selflimit
upper
respiratori
infect
becom
lower
respiratori
pathogen
high
mortal
unknown
second
sinc
merscov
ineffici
util
bat
cell
entri
limit
abil
persist
anim
discuss
camel
effici
carrier
merscov
whether
earli
transfer
camel
occur
provid
necessari
reservoir
amplif
unknown
larg
fraction
case
camel
serv
primari
sourc
infect
greater
dromedari
camel
arabian
peninsula
north
africa
seroposit
activ
shed
viru
suggest
high
level
suscept
infect
camel
develop
selflimit
upper
respiratori
infect
mark
high
viral
excret
exceed
pfuml
camelid
serv
natur
host
alpaca
hous
proxim
camel
high
seroposit
rate
demonstr
opportun
addit
reservoir
infect
global
trade
exot
anim
palm
civet
serv
vector
transmiss
sarscov
provid
caution
regard
animalrel
spread
merscov
phylogenet
speci
restrict
suscept
merscov
infect
sever
limit
develop
anim
model
diseas
primat
includ
rhesu
macaqu
marmoset
transgen
mice
express
human
camelid
rabbit
assess
potenti
anim
model
howev
model
system
limit
rhesu
macaqu
develop
transient
pulmonari
infect
ill
wherea
marmoset
develop
sever
ill
follow
merscov
infect
question
whether
observ
patholog
relat
experiment
manipul
small
mammal
versu
effect
viral
infect
transgen
mice
constitut
express
human
develop
lethal
system
infect
includ
central
nervou
system
diseas
wherea
transgen
mice
express
human
driven
surfact
promot
transduc
adenoviralassoci
vector
express
human
develop
mild
transient
diseas
camel
alpaca
natur
host
merscov
infect
use
diseas
model
develop
selflimit
upper
respiratori
infect
differ
human
infect
moreov
consider
expens
difficulti
experiment
model
use
larg
anim
magnitud
merscov
viral
load
nasopharyng
secret
blood
directli
correl
higher
mortal
studi
util
upper
respiratori
sampl
howev
clear
sinc
merscov
lower
respiratori
tract
pathogen
viral
load
lower
respiratori
sampl
minim
correl
risk
death
remain
dearth
studi
immunolog
merscov
infect
even
less
inform
compar
cohort
merscov
survivor
nonsurvivor
signific
literatur
regard
sarscov
immunolog
may
serv
paradigm
sarscov
b
cell
immun
shown
shortliv
antibodi
undetect
survivor
month
wherea
contrast
tcell
respons
longliv
persist
least
importantli
mous
studi
demonstr
cytotox
tcell
immun
sarscov
requir
viral
clearanc
surviv
lethal
infect
kinet
serolog
respons
merscov
show
bind
neutral
antibodi
appear
day
ill
reach
peak
day
later
small
saudi
arabian
studi
merscov
survivor
demonstr
persist
neutral
antibodi
almost
role
neutral
antibodi
viral
clearanc
howev
clear
korean
studi
patient
show
clear
differ
pattern
time
bind
antibodi
develop
sever
vs
nonsever
diseas
wherea
appear
neutral
antibodi
delay
day
sever
diseas
appar
reach
titer
rapidli
notabl
patient
sever
nonsever
diseas
develop
neutral
antibodi
greater
studi
person
saudi
arabia
found
patient
complet
data
demonstr
bind
neutral
antibodi
pairwis
correl
found
associ
presenc
neutral
antibodi
viral
clearanc
thu
role
neutral
antibodi
merscov
diseas
outcom
establish
final
one
could
question
whether
subclin
nonleth
infect
provid
longterm
protect
immun
recurr
merscov
infect
consid
fact
camel
high
seropreval
merscov
would
expect
camel
worker
would
recurr
merscov
exposur
yet
larg
seroepidemiolog
survey
camel
worker
saudi
arabia
found
low
preval
antimerscov
antibodi
suggest
antibodi
may
fact
persist
moreov
fact
mani
camel
exposur
continu
present
merscov
infect
also
suggest
prior
exposur
may
provid
longterm
immun
fall
earli
winter
intern
symposia
vaccin
drug
develop
merscov
held
seoul
korea
riyadh
saudi
arabia
geneva
switzerland
merscov
vaccin
discuss
includ
viral
vector
protein
subunit
nanoparticl
plasmid
dna
vaccin
direct
envelop
protein
receptor
bind
domain
rbd
protein
viral
vector
vaccin
candid
includ
adenovir
associ
vector
base
chimpanze
serotyp
human
serotyp
poxviru
vector
base
modifi
vaccinia
ankara
strain
attenu
measl
viru
vector
protein
base
vaccin
includ
rbd
subunit
vaccin
trimer
fulllength
protein
nanoparticl
sequenc
engin
rbd
subunit
allow
product
vaccin
candid
greater
microneutr
titer
dna
vaccin
includ
dnaprim
proteinboost
base
wildtyp
fulllength
protein
protein
boost
respect
second
dna
vaccin
encod
consensu
protein
group
assess
variabl
wildtyp
protein
construct
work
shown
inclus
full
cytoplasm
domain
transmembran
domain
dna
construct
critic
immunogen
increas
immunogen
balanc
ratio
subunit
vaccin
vs
full
length
construct
weight
toward
respons
one
dna
vaccin
progress
human
clinic
trial
tabl
ongo
list
vaccin
also
publish
world
health
organ
http
wwwwhointimmuniza
tionresearchvaccinepipelinetrackerspreadsheeten
pauciti
immunolog
studi
either
sar
mer
coronavirus
one
specul
properti
ideal
merscov
vaccin
possess
lack
ideal
anim
model
merscov
serv
impedi
vaccin
develop
need
robust
cytotox
tcell
respons
surviv
viral
clearanc
clinic
trial
gov
design
date
enter
clinic
trial
gov
codevelop
geneon
life
scienc
inc
inovio
pharmaceut
inc
indic
studi
complet
enrol
abbrevi
md
maryland
suggest
anim
model
sarscov
studi
sar
survivor
limit
data
merscov
recov
patient
show
earli
bind
antibodi
respons
may
benefici
wherea
role
neutral
antibodi
unclear
role
cellular
immun
respons
merscov
rel
import
humor
cellular
immun
prevent
infect
yet
character
phase
studi
synthet
consensu
dna
plasmid
vaccin
singl
merscov
vaccin
candid
fulllength
protein
consensu
dna
vaccin
progress
human
clinic
trial
tabl
total
particip
assign
one
dose
level
mg
mg
mg
administ
day
week
week
via
intramuscular
im
inject
follow
electropor
ep
addit
studi
assess
rel
immunogen
intraderm
id
vaccin
administr
follow
ep
provid
detail
optim
vaccin
dose
design
conduct
efficaci
trial
merscov
may
daunt
task
epidemiolog
merscov
vastli
differ
start
outbreak
fewer
case
scatter
across
saudi
arabia
except
singl
larg
outbreak
seoul
korea
minim
transmiss
merscov
outsid
saudi
arabia
merscov
remain
endem
saudi
arabia
approxim
case
diagnos
monthli
vigil
maintain
strict
infect
control
procedur
significantli
reduc
new
case
among
healthcar
worker
hcw
spread
patient
healthcar
facil
addit
outbreak
outsid
arabian
peninsula
akin
korean
epidem
septemb
addit
mani
incid
infect
occur
individu
without
clear
epidemiolog
link
known
case
camel
factor
creat
challeng
design
definit
efficaci
trial
merscov
vaccin
basic
protocol
design
includ
ring
vaccin
studi
prevent
infect
among
direct
contact
studi
prevent
incid
infect
group
highest
risk
merscov
infect
ring
vaccin
success
use
ebola
epidem
made
possibl
fact
famili
healthcar
contact
high
risk
infect
transmiss
merscov
within
famili
unit
document
howev
case
appear
anomali
healthcar
set
infect
control
measur
significantli
reduc
spread
patient
hcw
thu
ringvaccin
strategi
would
requir
enrol
larg
number
recruit
famili
contact
reach
suffici
number
event
achiev
statist
power
second
studi
design
populationbas
vaccin
highest
risk
infect
hcw
resid
town
villag
highest
histor
case
rate
camel
contact
key
challeng
best
identifi
past
merscov
exposur
group
determin
individu
may
preexist
protect
b
cell
andor
cell
immun
whether
vaccin
studi
restrict
nonimmun
individu
interest
question
sinc
alreadi
demonstr
minor
individu
repeat
exposur
camel
detect
antibodi
suggest
immun
may
persist
fact
camel
exposur
continu
known
risk
infect
rais
question
whether
nonleth
infect
result
protect
immun
whether
immun
persist
thu
studi
riskgroup
could
stratifi
without
document
merscov
immun
respons
whether
exposur
defin
epidemiolog
exposur
presenc
bind
antibodi
neutral
antibodi
cell
respons
also
unknown
final
third
clinic
trial
design
could
focu
highest
risk
sever
infect
studi
would
easili
discern
vaccin
effect
sinc
primari
outcom
would
compar
morbid
death
vaccin
placebo
howev
highest
risk
sever
diseas
includ
elderli
underli
ill
cardiac
pulmonari
renal
diseas
may
limit
vaccin
immun
respons
merscov
vaccin
key
challeng
abil
conduct
definit
efficaci
trial
decreas
incid
case
overal
fact
primari
case
geograph
separ
primari
factor
make
trial
difficult
efficaci
trial
prevent
primari
infect
may
possibl
restrict
saudi
villag
town
greatest
number
known
case
sinc
ongo
nosocomi
spread
still
document
includ
small
outbreak
june
studi
prevent
infect
health
care
worker
may
feasibl
interest
merscov
camel
vaccin
may
limit
human
diseas
provid
altern
path
licensur
via
anim
rule
although
vaccin
develop
camel
present
uniqu
challeng
indic
epidemiolog
infect
merscov
vaccin
would
primarili
target
popul
endem
countri
especi
healthcar
industri
contact
camel
secondari
market
exist
travel
arabian
peninsula
perhap
includ
make
pilgrimag
hajj
stockpil
govern
futur
outbreak
zika
viru
member
flaviviru
famili
includ
dengu
west
nile
yellow
fever
virus
zika
viru
discov
part
studi
map
geograph
extent
yellow
fever
viru
uganda
time
discoveri
zika
preval
subsaharan
africa
tropic
asia
seropreval
rate
high
region
except
small
outbreak
yap
island
zika
viru
remain
essenti
unknown
outsid
africa
asia
zika
outbreak
french
polynesia
last
month
result
approxim
diagnos
case
consist
symptom
estim
island
resid
infect
zika
viru
quickli
spread
eastward
across
south
pacif
first
case
document
brazil
earli
interestingli
report
suggest
zika
epidem
brazil
may
start
earli
aed
speci
mosquito
particular
ae
aegypti
repres
domin
vector
transmiss
zika
viru
mosquito
speci
may
harbor
zika
viru
may
abl
transmit
infect
aed
albopticu
temper
speci
carri
zika
viru
transmit
infect
zika
transmit
transovari
ie
vertic
across
mosquito
gener
sexual
transmiss
zika
viru
well
document
zika
persist
semin
fluid
week
follow
infect
zika
also
detect
saliva
breast
milk
tear
zika
viru
infect
typic
selflimit
mani
case
minim
symptomat
estim
day
incub
period
viral
prodrom
gener
achi
myalgia
arthralgia
sore
throat
headach
may
follow
gener
maculopapular
rash
involv
palm
sole
retroorbit
pain
conjunct
common
fever
present
usual
lowgrad
complic
zika
viru
infect
divid
neurolog
genitourinari
zika
viru
neurotrop
link
made
earli
mice
adult
zika
viru
caus
guillainbarr
e
syndrom
gb
attack
rate
estim
almost
case
infect
unlik
classic
gb
follow
campylobact
gastroenter
fraction
patient
present
zikainduc
gb
circul
antigangliosid
autoantibodi
consist
pattern
express
autoantibodi
complic
includ
enceph
acut
demyelin
encephalomyel
adem
seizur
women
infect
zika
viru
pregnanc
risk
fetal
infect
associ
zika
viru
infect
microcephali
first
report
pernambuco
state
brazil
novemb
perceiv
absenc
microcephali
french
polynesian
outbreak
resolv
retrospect
studi
found
preval
microcephali
infant
born
mother
infect
pregnanc
howev
recent
studi
estim
infant
women
infect
end
st
trimest
may
affect
addit
aspect
congenit
zika
viru
infect
includ
intracrani
calcif
ocular
calcif
retin
defect
auditori
defect
arthrogryposi
pregnant
women
develop
prolong
zika
viremia
resolv
deliveri
infant
genitourinari
complic
zika
viru
begin
understood
note
zika
detect
semin
fluid
prolong
period
follow
infect
omin
complic
mice
yet
document
human
infect
young
mice
caus
direct
testicular
infect
result
testicular
atrophi
infertil
prior
diagnost
test
zika
viru
infect
nonexist
outsid
academ
laboratori
sinc
time
multipl
pcr
serolog
assay
gain
emerg
use
author
eua
us
food
drug
administr
fda
diagnosi
zika
viru
infect
remain
complic
epitop
crossreact
zika
viru
flavivirus
affect
serolog
assay
rel
pauciti
symptom
may
delay
sampl
collect
pcrbase
assay
coupl
rel
short
period
viremia
need
detect
viru
bodi
fluid
urin
andor
semen
review
subject
reader
refer
elsewher
clinic
studi
demonstr
mark
variat
sensit
detect
differ
test
method
rais
cautionari
note
viral
detect
pcr
mainstay
diagnosi
consid
gold
standard
determin
acut
ill
clinic
trial
zika
viru
viremia
typic
last
week
wherea
zika
detect
urin
week
even
longer
semen
serolog
detect
zika
viru
infect
target
either
viral
envelop
protein
incorpor
whole
viru
assay
use
assay
jeong
et
al
determin
kinet
antibodi
format
person
travelrel
zika
viru
infect
igm
respons
present
within
day
present
persist
day
igg
respons
detect
approxim
postpresent
persist
length
studi
consist
prior
small
studi
zika
uniqu
abl
suppress
human
innat
immun
respons
zika
demonstr
downregul
type
interferon
ifn
respons
dendrit
cell
impair
phosphoryl
other
find
zika
viru
nonstructur
protein
result
proteasom
degrad
cell
latter
phenomenon
also
seen
dengu
viru
contrast
human
zika
affect
murin
function
rag
mice
lack
matur
b
cell
cell
remain
resist
zika
viru
infect
addit
wildtyp
mice
whose
innat
immun
system
impair
monoclon
antibodi
mab
type
ifn
receptor
similarli
resist
zika
viru
contrast
rag
mice
treat
type
ifn
receptor
mab
develop
neurolog
testicular
infect
thu
human
sinc
zika
downregul
innat
immun
system
vaccin
induc
adapt
immun
respons
gain
import
especi
regard
neurolog
testicular
infect
zika
viru
also
shown
abl
evad
immun
system
despit
presenc
neutral
antibodi
macaqu
rapidli
resolv
viremia
follow
experiment
infect
correl
onset
antibodi
format
cell
mediat
immun
howev
despit
presenc
neutral
bind
antibodi
induct
immun
respons
zika
persist
lymph
node
central
nervou
system
month
notabl
cn
infect
macaqu
associ
transcriptom
evid
upregul
mtor
inflammatori
pathway
key
pathway
dysregul
zika
protein
increas
autophagi
neural
progenitor
cell
data
would
suggest
import
prevent
infect
establish
persist
protect
site
question
whether
prior
immun
denv
provid
cross
protect
zika
viru
enhanc
zika
viru
infect
yet
resolv
denv
heterolog
secondari
infect
ie
differ
serotyp
approxim
postinfect
carri
increas
risk
dengu
hemorrhag
fever
dhf
wherea
earlier
exposur
protect
studi
halstead
demonstr
sever
secondari
infect
correl
presenc
nonneutr
antibodi
sera
increas
vitro
cellular
viral
entri
phenomenon
term
antibodi
depend
enhanc
ade
infect
one
prospect
studi
thai
children
serum
collect
month
period
secondari
infect
sera
children
asymptomat
secondari
denv
infect
demonstr
ade
vs
sever
infect
contrast
subsequ
prospect
thai
studi
greater
children
secondari
denv
infect
demonstr
relationship
sever
infect
ade
henderson
et
al
primat
studi
demonstr
cross
protect
anim
infect
one
flaviviru
challeng
second
differ
flaviviru
wherea
later
vitro
studi
demonstr
antibodi
depend
enhanc
ade
infect
denv
yellow
fever
flavivirus
vitro
ade
also
demonstr
zika
viru
presenc
flaviviru
antibodi
denv
andor
west
nile
viru
wnv
mab
denv
fusion
loop
domain
lower
affin
zika
viru
induc
ade
wherea
mab
envelop
domain
inhibit
ade
other
found
prior
antibodi
denv
serotyp
envelop
domain
iii
associ
higher
zika
neutral
titer
contrast
sera
collect
subject
acut
denv
infect
sera
collect
later
convalesc
period
demonstr
crossreact
denv
zika
viru
convers
antibodi
zika
viru
envelop
domain
ii
poorli
neutral
enhanc
dengu
viru
infect
wherea
domain
iii
antibodi
specif
protect
importantli
clinic
correl
crossflaviviru
ade
far
lack
studi
pcrposit
pregnant
women
found
correl
p
presenc
prior
denv
antibodi
diseas
sever
relationship
zika
viral
load
advers
outcom
fetal
loss
thu
clinic
implic
prior
flaviviru
immun
remain
unansw
present
correl
protect
would
relat
vaccin
develop
determin
goal
would
prevent
infect
establish
viral
reservoir
cn
lymph
node
even
test
induct
high
level
bind
antibodi
may
suffici
prevent
zika
induc
immun
dysregul
viral
clearanc
induct
neutral
antibodi
consid
mani
ideal
limit
abl
clear
reservoir
cn
lymph
node
cautionari
final
ideal
vaccin
would
also
induc
cellular
immun
especi
tcell
respons
may
serv
prevent
cn
testicular
damag
despit
dysregul
type
ifn
pathway
caus
zika
protein
key
target
popul
zika
viru
vaccin
women
childbear
potenti
goal
prevent
congenit
zika
viru
infect
vaccin
pregnanc
howev
viabl
strategi
even
vaccin
deem
safe
sinc
pregnanc
may
suspect
mid
latter
part
st
trimest
may
insuffici
time
develop
protect
immun
respons
risk
fetu
greatest
therefor
vaccin
program
target
postpubert
femal
child
bear
potenti
male
sexual
partner
male
observ
mice
zika
infect
test
caus
atrophi
infertil
rais
question
whether
vaccin
warrant
earli
childhood
vaccin
candid
develop
includ
liveattenu
viral
vaccin
live
chimer
vaccin
purifi
inactiv
kill
vaccin
piv
viral
vector
vaccin
base
measl
adenoassoci
viru
aav
vesicular
stomat
viru
vsv
vaccinia
platform
subunit
nanoparticl
protein
base
vaccin
nucleic
acid
vaccin
use
dna
mrna
approach
see
also
world
health
organ
list
http
wwwwhointimmunizationresearch
vaccinepipelinetrackerspreadsheeten
date
review
preclin
data
one
piv
vaccin
attenu
liveviru
vaccin
dna
vaccin
mrna
vaccin
separ
aavbas
vaccin
subunit
vaccin
publish
three
dna
vaccin
mrna
vaccin
piv
vaccin
advanc
phase
clinic
trial
tabl
correl
protect
immun
zika
vaccin
area
intens
studi
addit
rel
import
humor
cellular
immun
yet
uncharacter
importantli
standard
assay
develop
correl
immun
respons
outcom
zika
viru
transmiss
ongo
affect
countri
america
incid
case
dramat
declin
present
potenti
barrier
efficaci
trial
correl
within
endem
region
mani
alreadi
infect
limit
number
risk
thu
race
get
vaccin
candid
region
activ
transmiss
two
trial
dna
vaccin
zpiv
begun
enrol
zika
endem
region
tabl
uniqu
safeti
consider
rais
discuss
zika
viru
vaccin
develop
antibodydepend
enhanc
infect
ade
gb
ade
vitro
phenomenon
initi
document
dengu
viru
observ
flavivirus
includ
zika
presenc
enhanc
antibodi
postul
risk
dengu
hemorrhag
fever
dhf
prospect
clinic
studi
demonstr
correl
presenc
enhanc
antibodi
preinfect
serum
sever
dengu
viru
infect
one
caveat
zika
vaccin
find
studi
liveviru
chimer
dengu
vaccin
young
children
dengueseroneg
adult
greater
risk
dhf
start
postvaccin
discuss
clinic
correl
crossflaviviru
reactiv
yet
unresolv
epidemiolog
data
suggest
current
zika
viru
epidem
increas
risk
dhf
present
one
studi
pregnant
femal
show
evid
differ
diseas
sever
relat
prior
denv
seroposit
studi
shown
prior
denv
serotyp
infect
may
associ
increas
neutral
antibodi
titer
could
result
greater
protect
gb
complic
zika
viru
infect
well
document
french
polynesian
brazilian
american
outbreak
studi
french
polynesia
show
contrast
classic
case
gb
minor
patient
detect
antigangliosid
antibodi
present
consist
pattern
autoantibodi
date
molecular
mimic
similar
observ
campylobact
lipooligosaccharid
axon
gangliosid
document
zika
contrast
mer
zika
remain
endem
efficaci
trial
remain
possibl
key
challeng
abil
move
phase
iiiii
disappear
zika
target
region
fact
countri
brazil
appear
experienc
repeat
cycl
infect
promis
conduct
trial
zika
vaccin
develop
driven
primarili
desir
prevent
congenit
infect
women
becom
infect
pregnanc
secondari
target
prevent
neurolog
complic
gb
possibl
prevent
infect
male
prevent
testicular
damag
primari
target
popul
vaccin
program
differ
somewhat
femal
childbear
potenti
male
birth
end
childbear
year
differ
age
male
femal
relat
current
uncertainti
age
test
prone
infect
lack
evid
direct
infect
ovari
pregnant
women
would
consid
primari
target
popul
sinc
initi
vaccin
seri
pregnanc
diagnos
may
induc
protect
immun
end
st
trimest
fetu
risk
addit
safeti
viral
vector
liveattenu
vaccin
unknown
pregnanc
addit
target
popul
travel
endem
region
live
region
aed
speci
mosquito
especi
ae
aegypti
endem
excel
sourc
inform
zika
vaccin
therapeut
plan
publish
world
health
organ
http
vaccin
develop
infecti
diseas
uniqu
challeng
time
emerg
littl
may
known
pathogenesi
epidemiolog
epidem
potenti
new
infecti
agent
merscov
zika
viru
highlight
potenti
emerg
futur
pathogen
merscov
appear
repres
novel
genet
variant
minim
pathogen
bat
coronaviru
howev
question
still
remain
one
strain
mortal
caus
lower
respiratori
diseas
caus
selflimit
upper
respiratori
ill
moreov
sinc
merscov
preferenti
bind
human
like
variant
bat
strain
prefer
bat
would
emerg
propag
within
bat
also
mysteri
zika
viru
global
augment
spread
diseas
nonendem
region
howev
mean
transmiss
still
unknown
continu
genet
modif
human
anim
virus
continu
pose
potenti
threat
spread
diseas
previous
remot
region
merscov
discoveri
novel
coronaviru
singl
saudi
arabian
patient
caus
concern
alarm
case
appear
isol
event
case
number
region
global
increas
quickli
escal
concern
heighten
howev
appreci
potenti
global
threat
organ
delay
year
zika
viru
known
entiti
time
reemerg
discov
almost
zika
previous
consid
caus
ill
similar
much
less
sever
either
dengu
chikungunya
nascent
effort
develop
vaccin
zika
viru
lack
known
sever
complic
temper
research
effort
note
zika
associ
microcephali
congenit
defect
latter
part
provid
impetu
hasten
vaccin
discoveri
diseas
advantag
occur
time
multipl
platform
technolog
exist
mani
platform
could
respond
new
pathogen
minim
genet
modif
experi
allow
classic
vaccin
also
undergo
rapid
modif
although
case
structur
consider
eg
protein
structur
antigen
present
uniqu
advers
event
eg
eosinophilc
pulmonari
inflamm
induc
whole
inactiv
sar
viru
vaccin
time
viral
challeng
requir
note
respons
eid
robust
mani
academ
laboratori
pharmaceut
firm
initi
vaccin
program
ill
character
chang
epidemiolog
time
vaccin
candid
enter
clinic
trial
incid
diseas
significantli
declin
merscov
current
endem
rate
incid
infect
case
one
region
creat
signific
challeng
ie
potenti
requir
larg
number
particip
demonstr
efficaci
region
restrict
merscov
coupl
approxim
case
per
year
limit
commerci
potenti
vaccin
like
key
factor
singl
vaccin
enter
clinic
trial
zika
viru
vaccin
greater
commerci
potenti
rapid
increas
declin
epidem
case
affect
region
requir
prognost
case
occur
futur
rather
present
sinc
least
lead
time
logist
prepar
countryspecif
regulatori
approv
local
review
board
approv
zika
viru
merscov
epidem
requir
uniqu
approach
vaccin
develop
promot
intens
develop
effort
numer
academ
commerci
entiti
enabl
rapid
respons
respect
diseas
challeng
diseas
eid
pose
uniqu
challeng
clinic
trial
design
vaccin
develop
comprehens
strategi
includ
adequ
fund
requir
ensur
earli
enthusiasm
advanc
academ
laboratori
mani
biotechnolog
compani
continu
later
develop
wither
vine
dr
maslow
chief
medic
offic
geneon
life
scienc
inc
develop
dna
vaccin
dna
therapeut
includ
vaccin
direct
merscov
zika
viru
dr
maslow
own
stock
stock
option
geneon
dr
maslow
also
own
stock
inovio
pharmaceut
inc
codevelop
merscov
zika
viru
vaccin
